Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: Voller Fokus auf NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 1888 | ISIN: DEXXXXXXX122 | Ticker-Symbol: -
Branche
Pharma
Aktienmarkt
nicht börsennotiert
1-Jahres-Chart  (nicht börsennotiert)
BOEHRINGER INGELHEIM GMBH Chart 1 Jahr
PR Newswire
839 Leser
Artikel bewerten:
(2)

Veeva Systems: Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory Operations in Animal Health

Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed

BARCELONA, Spain, Feb. 14, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.

Veeva Systems

"Veeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making," said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim. "This will allow us to execute and innovate faster to improve the lives of animals."

Boehringer Ingelheim will use Veeva Vault CTMS in its animal health business unit to manage and monitor trials and Veeva Vault eTMF for real-time inspection readiness, visibility, and control. The company will also use Vault RIM applications, including Veeva Vault Registrations, Veeva Vault Submissions, and Veeva Vault Submissions Archive for advanced regulatory processes. Connecting these applications on a single cloud platform will enable real-time access to data and seamless information exchange.

"Boehringer Ingelheim is driving innovation to accelerate the development of new treatments for animals," said Thomas Reith, corporate vice president, IT research, development, and medicine at Boehringer Ingelheim. "By establishing a centralized and digital foundation with Veeva, we can deliver a better user experience for our teams, and offer lean, end-to-end processes for speed and agility."

"We're proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes," said Stefan Jahnecke, vice president of animal health strategy at Veeva. "Veeva Vault Clinical and Veeva Vault RIM will help Boehringer Ingelheim increase data integrity and provide the visibility to quickly adapt to changing business requirements."

Vault Clinical and Vault RIM are part of Veeva Development Cloud, the technology foundation for product development across clinical, regulatory, quality, and safety. To learn more, visit veeva.com/eu/DevelopmentCloud.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:



Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com


Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/boehringer-ingelheim-partners-with-veeva-to-advance-its-clinical-and-regulatory-operations-in-animal-health-302061438.html

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.